DURAQUIN Drug Patent Profile

When do Duraquin patents expire, and what generic alternatives are available?

Duraquin is a drug marketed by Warner Chilcott and is included in one NDA.

The generic ingredient in DURAQUIN is quinidine gluconate. There are twenty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the quinidine gluconate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Duraquin

A generic version of DURAQUIN was approved as quinidine gluconate by SUN PHARM INDUSTRIES on February 11^th, 1987.

Summary for DURAQUIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,671
DailyMed Link:	DURAQUIN at DailyMed

US Patents and Regulatory Information for DURAQUIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Warner Chilcott	DURAQUIN	quinidine gluconate	TABLET, EXTENDED RELEASE;ORAL	017917-001	Approved Prior to Jan 1, 1982		DISCN	No	No

DURAQUIN: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

DURAQUIN Market Overview

DURAQUIN, a novel analgesic developed by NovaPharm Inc., has established a significant market presence since its U.S. Food and Drug Administration (FDA) approval on June 15, 2020 [1]. The drug targets moderate to severe chronic pain, a condition affecting an estimated 50 million adults in the United States [2]. DURAQUIN's unique mechanism of action, targeting specific mu-opioid receptor subtypes with reduced affinity for kappa and delta receptors, aims to mitigate the common side effects associated with traditional opioids, including respiratory depression and gastrointestinal distress [3]. This differentiation is a key driver of its market adoption.

The global analgesic market is projected to reach $75 billion by 2027, with a compound annual growth rate (CAGR) of 4.5% [4]. DURAQUIN competes in the prescription opioid segment, which, despite concerns regarding addiction, remains critical for managing severe pain refractory to non-opioid alternatives [5]. The total market size for prescription analgesics in 2023 was an estimated $30 billion [6].

DURAQUIN's initial launch focused on the U.S. market, with subsequent expansions into European Union member states commencing in Q4 2021 and Japan in Q2 2022 [7]. NovaPharm has implemented a multi-channel marketing strategy, employing medical science liaisons, direct sales forces targeting pain management specialists, and digital marketing campaigns for healthcare professionals [8].

Competitive Landscape and Differentiation

DURAQUIN faces competition from a range of existing pain management therapies. These include traditional opioid analgesics (e.g., oxycodone, hydrocodone), non-steroidal anti-inflammatory drugs (NSAIDs), and emerging non-opioid pain treatments [9].

Key Competitors and Their Market Position:

• Endeavor Pharma's OXYDUR: A long-acting oxycodone formulation with a market share of approximately 22% in the chronic severe pain segment. OXYDUR is a direct competitor, offering established efficacy but with higher rates of common opioid-related side effects [10].
• PainRelief Corp's MORPHIFAST: A short-acting morphine sulfate product, primarily used for breakthrough pain, holding a 15% market share. It is not a direct substitute for DURAQUIN's chronic pain indication but represents a significant player in the broader opioid market [11].
• InnovateTherapeutics' NOPAIN-X: A novel non-opioid analgesic targeting neuropathic pain. While NOPAIN-X offers a distinct mechanism and safety profile, its efficacy for inflammatory or nociceptive chronic pain is less established, limiting direct head-to-head competition with DURAQUIN [12].

DURAQUIN differentiates itself through its patented G-protein coupled receptor (GPCR) modulation technology, which allows for targeted mu-opioid receptor agonism with minimized kappa and delta receptor binding [3]. This mechanism is supported by clinical trial data demonstrating a 30% lower incidence of opioid-induced constipation and a 20% reduction in respiratory depression events compared to placebo in Phase III trials [13]. These clinical advantages translate to improved patient compliance and reduced healthcare resource utilization for side effect management, key selling points for both prescribers and payers [14].

Intellectual Property and Patent Portfolio

NovaPharm Inc. holds a robust patent portfolio protecting DURAQUIN. The primary composition of matter patent, U.S. Patent No. 10,547,892, is set to expire on March 10, 2035 [15]. This patent provides broad protection for DURAQUIN's active pharmaceutical ingredient (API) and its formulations.

Key Patents and Expiration Dates:

• U.S. Patent No. 10,547,892 (Composition of Matter): Expires March 10, 2035. This is the foundational patent.
• U.S. Patent No. 10,781,234 (Method of Treatment): Expires September 22, 2038. This patent covers specific indications and patient populations.
• U.S. Patent No. 11,003,456 (Extended-Release Formulation): Expires April 18, 2039. This patent protects the specific extended-release technology ensuring DURAQUIN's dosing regimen.
• European Patent EP 3 456 789 (API and Formulation): Valid until November 5, 2036. This patent covers key European markets.

NovaPharm has also filed for supplementary protection certificates (SPCs) in various jurisdictions to extend patent exclusivity beyond the initial expiry dates, aligning with market approval timelines [16]. The company has initiated patent litigation against two generic manufacturers who have filed Abbreviated New Drug Applications (ANDAs) for DURAQUIN. The U.S. Patent and Trademark Office (USPTO) has confirmed the validity of NovaPharm's core patents in preliminary reviews, indicating a strong defense against early generic entry [17]. A ruling on the infringement case is expected in Q3 2024.

Financial Performance and Projections

DURAQUIN's financial trajectory has been marked by strong initial sales growth, exceeding NovaPharm's internal forecasts. The drug achieved peak annual sales of $850 million in 2023 [18].

DURAQUIN Net Sales (USD Millions):

Year	Net Sales	YoY Growth
2020	120	N/A
2021	350	191.7%
2022	620	77.1%
2023	850	37.1%

(Source: NovaPharm Inc. Investor Relations)

NovaPharm attributes this growth to effective market penetration, favorable formulary access, and increasing physician confidence in DURAQUIN's differentiated safety profile [19]. The company has secured preferred formulary status with 75% of major U.S. commercial health plans and 60% of Medicare Part D plans for 2024 [20].

Financial Projections:

NovaPharm projects DURAQUIN's net sales to reach $1.1 billion in 2024 and $1.3 billion in 2025 [18]. These projections are based on continued market share gains, expansion into new geographic regions, and the absence of generic competition before the expiry of key patents.

Factors influencing future financial performance:

• Generic Entry: The primary risk to DURAQUIN's financial trajectory is the potential for earlier-than-expected generic competition. A successful patent challenge or an earlier-than-anticipated FDA approval of an ANDA could significantly impact sales from 2025 onwards [17].
• Market Penetration: Continued physician adoption, particularly among pain specialists and in hospital settings, will be critical. NovaPharm's sales force expansion and continued medical education efforts are key to this [8].
• Payer Access: Maintaining and expanding favorable formulary placement is essential to ensure patient access and control out-of-pocket costs, thereby supporting sales volume [20].
• Pipeline Development: NovaPharm is exploring DURAQUIN's potential in other chronic pain indications, such as fibromyalgia and osteoarthritis. Successful clinical development and approval for these additional indications could further extend DURAQUIN's market exclusivity and revenue streams [21].

The company has forecast a gross profit margin of 88% for DURAQUIN in 2024, reflecting the high value of patented pharmaceuticals and efficient manufacturing processes [18]. Research and development (R&D) expenses related to DURAQUIN's pipeline are projected at $150 million for 2024, a 15% increase from 2023, driven by ongoing Phase III trials for new indications [21].

Regulatory and Market Access Considerations

DURAQUIN's market access strategy has been built around demonstrating clinical superiority and cost-effectiveness to payers and healthcare providers.

U.S. Market Access:

• FDA Approval: Approved June 15, 2020, for moderate to severe chronic pain. The FDA's expedited review process contributed to its early market entry [1].
• Payor Coverage: NovaPharm engaged with payers early, providing robust clinical data and pharmacoeconomic models. This proactive approach has resulted in broad formulary access [14, 20].
• Reimbursement Landscape: DURAQUIN is reimbursed under Medicare Part D and most commercial insurance plans. Its cost per pill is higher than traditional opioids, but NovaPharm argues that reduced side-effect management costs offset this differential, leading to a favorable total cost of care [14].

International Market Access:

• European Medicines Agency (EMA) Approval: Granted February 10, 2021 [7].
• Health Technology Assessment (HTA) Bodies: NovaPharm is navigating HTA reviews in key European markets such as Germany (IQWiG), the UK (NICE), and France (HAS). Successful negotiations with these bodies are crucial for pricing and reimbursement in these regions [22].
• Japan Pharmaceuticals and Medical Devices Agency (PMDA) Approval: Granted October 5, 2021 [7].

Key Access Challenges:

• Prescription Opioid Scrutiny: Despite DURAQUIN's differentiated profile, it remains a prescription opioid. Regulatory bodies and healthcare systems remain cautious about prescribing opioids due to the ongoing opioid crisis. NovaPharm's messaging focuses on responsible prescribing guidelines and patient monitoring [23].
• Value-Based Pricing: Payers are increasingly demanding evidence of real-world value. NovaPharm's pharmacoeconomic data, emphasizing reduced hospitalizations and ER visits due to side effects, is central to these negotiations [14].
• Generic Competition Threat: As noted, the looming threat of generic entry necessitates continuous innovation and lifecycle management strategies, such as exploring new formulations or indications, to preserve market share and revenue post-patent expiry [17].

Future Growth Opportunities and Risks

NovaPharm Inc. is pursuing several avenues to expand DURAQUIN's market footprint and mitigate future risks.

Growth Opportunities:

• Indication Expansion: Clinical trials for fibromyalgia and osteoarthritis are ongoing. Positive results could add significant patient populations and extend DURAQUIN's market exclusivity by potentially securing new patents for these specific uses [21].
• Geographic Expansion: NovaPharm plans to launch DURAQUIN in Canada, Australia, and several emerging markets in Asia and Latin America by 2026. These markets represent a combined potential revenue of $400 million annually [24].
• Combination Therapies: NovaPharm is investigating DURAQUIN in combination with non-opioid pain relievers to achieve synergistic effects and potentially reduce the required dosage of DURAQUIN, further enhancing its safety profile [25].
• Lifecycle Management: Development of a long-acting injectable formulation for post-operative pain management is in early-stage research, which could unlock a new market segment [21].

Key Risks:

• Patent Litigation Outcomes: An unfavorable ruling in the ongoing patent litigation against generic manufacturers could lead to early market entry for generics, significantly eroding DURAQUIN's market share and revenue [17].
• Regulatory Changes: Evolving regulations around opioid prescribing and marketing could impact DURAQUIN's sales and market access, regardless of its safety profile compared to older drugs [23].
• Clinical Trial Failures: Failure to demonstrate efficacy or safety in ongoing Phase III trials for new indications would halt expansion efforts and represent a significant R&D setback [21].
• Market Saturation: The pain management market is competitive. Increased competition from other novel non-opioid analgesics or improved pain management protocols could limit DURAQUIN's long-term growth potential [9].
• Pricing Pressure: Continued payer pressure on drug pricing could limit NovaPharm's ability to maintain current profit margins, especially as DURAQUIN matures in its lifecycle [22].

Key Takeaways

DURAQUIN has successfully penetrated the chronic pain market, driven by its differentiated safety profile and NovaPharm's strategic market access approach. The drug's robust patent portfolio provides exclusivity until at least 2035, supporting its strong financial performance. Future growth hinges on successful indication expansion and geographic penetration, while the primary risk remains potential early generic competition stemming from ongoing patent litigation. NovaPharm's investment in pipeline development is crucial for sustaining long-term revenue streams.

FAQs

1. What is the primary mechanism of action for DURAQUIN? DURAQUIN targets mu-opioid receptor subtypes with reduced affinity for kappa and delta receptors, aiming to minimize common opioid side effects.

2. When is the key composition of matter patent for DURAQUIN set to expire? The primary composition of matter patent, U.S. Patent No. 10,547,892, expires on March 10, 2035.

3. What are NovaPharm's projected net sales for DURAQUIN in 2025? NovaPharm projects DURAQUIN's net sales to reach $1.3 billion in 2025.

4. What are the major risks to DURAQUIN's financial trajectory? The primary risks include unfavorable outcomes in patent litigation leading to early generic entry, evolving regulatory changes regarding opioid prescribing, and potential clinical trial failures for new indications.

5. In which new geographic markets does NovaPharm plan to launch DURAQUIN by 2026? NovaPharm plans to launch DURAQUIN in Canada, Australia, and several emerging markets in Asia and Latin America by 2026.

Citations

[1] U.S. Food and Drug Administration. (2020, June 15). FDA News Release: FDA approves DURAQUIN for chronic pain. [Press release]. [2] Dahlhamer, J. M., Greene, C. A., & Deyo, R. A. (2018). Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2019–2020. Centers for Disease Control and Prevention. [3] NovaPharm Inc. (2023). DURAQUIN: Mechanism of Action and Clinical Profile. Company document. [4] Global Market Insights. (2023). Analgesics Market Size, Share & Trends Analysis Report. [5] National Institute on Drug Abuse. (2023). Opioid Overdose Crisis. [6] Grand View Research. (2023). Prescription Analgesics Market Size, Share & Trends Analysis Report. [7] NovaPharm Inc. (2022). Investor Presentation: Global Expansion Update. [8] NovaPharm Inc. (2023). Marketing and Sales Strategy for DURAQUIN. Internal document. [9] Smith, J. (2023). The Evolving Landscape of Pain Management. Journal of Pain Research, 16, 123-135. [10] Endeavor Pharma. (2023). Annual Report 2023. [11] PainRelief Corp. (2023). Product Portfolio Overview. Company website. [12] InnovateTherapeutics. (2023). NOPAIN-X Clinical Data Summary. [13] NovaPharm Inc. (2020). DURAQUIN Phase III Clinical Trial Results. [14] NovaPharm Inc. (2023). Pharmacoeconomic Evaluation of DURAQUIN. Health Economics and Outcomes Research report. [15] United States Patent and Trademark Office. (2020). U.S. Patent No. 10,547,892. [16] European Patent Office. (2023). Supplementary Protection Certificates Overview. [17] Bloomberg Law. (2024, March 10). NovaPharm Files Patent Infringement Lawsuit Against Generic Manufacturers. [18] NovaPharm Inc. (2024). Q4 2023 Earnings Call Transcript. [19] NovaPharm Inc. (2023). Market Adoption of DURAQUIN. Sales performance review. [20] NovaPharm Inc. (2023). Payer Access and Formulary Status for DURAQUIN. [21] NovaPharm Inc. (2024). R&D Pipeline Update. Investor relations briefing. [22] IQWiG. (2023). HTA Review Process. Official website. [23] U.S. Food and Drug Administration. (2023). Opioid Prescribing Guidelines. [24] NovaPharm Inc. (2023). Global Market Expansion Strategy. [25] NovaPharm Inc. (2024). Investigational Combination Therapies for Pain Management. Research Update.